يعرض 11 - 20 نتائج من 56 نتيجة بحث عن '"Medicaments - Eficàcia"', وقت الاستعلام: 0.98s تنقيح النتائج
  1. 11
    مؤتمر

    المساهمون: Àrea Assistencial, Servei Català de la Salut (CatSalut), Generalitat de Catalunya, Barcelona, Spain, Departament de Salut

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: The 44th IHF World Hospital Congress; 2021-11-08; Barcelona; Roig-Izquierdo M, Gasol M, Umbria M, Clapés J, Prat A, Corinne Z, et al. Registry of patients and treatments of hospital medicines in Catalonia: a tool to improve quality and efficiency of hospital drug use. Poster presented at: 44th IHF World Hospital Congress; 2021 November 8-11; Barcelona.; https://hdl.handle.net/11351/6825Test

  2. 12
    تقرير
  3. 13
    تقرير
  4. 14
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Schmid P Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. Sablin MP Department of Drug Development and Innovation, Institut Curie, Paris, France. Bergh J Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden. Im SA Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. Lu YS Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Martínez N Department of Oncology, Ramon y Cajal University Hospital, Madrid, Spain. Cortés J Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Oncology, IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Breast Cancer Research;23; https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01382-8Test; Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, et al. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Res. 2021 Jan 15;23:8.; https://hdl.handle.net/11351/6097Test; 000608053300001

  5. 15
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, O'Malley DM The Ohio State University, James Comprehensive Cancer Center, Columbus, OH, United States. Oaknin A Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Monk BJ Arizona Oncology (US Oncology Network), Creighton University School of Medicine, Phoenix, AZ, United States. Selle F Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France. Rojas C Centro de Investigacion Clinica, Bradford Hill, Santiago, Chile. Gladieff L Institut Claudius Regaud-Institut Universitaire du Cancer (IUCT)-Oncopole, Toulouse, France, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Gynecologic Oncology;163(2); https://doi.org/10.1016/j.ygyno.2021.08.018Test; O'Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021 Nov;163(2):274–80.; https://hdl.handle.net/11351/7789Test; 000714728500009

  6. 16
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Teira R Hospital de Sierrallana, Torrelavega, Spain. Diaz-Cuervo H Gilead Sciences, Medical Affairs, Stockley Park HEOR, Spain. Aragão F Maple Health Group, New York, New York, United States of America. NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisboa, Portugal. Marguet S Amaris Consulting, Health Economics and Market Access (HEMA), Levallois-Perret, France. de la Fuente B Hospital de Cabueñes, Gijón, Spain. Muñoz MJ Hospital de Basurto, Bilbao, Spain. Ribera E Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: PLoS ONE;16(4); https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249515Test; Teira R, Diaz-Cuervo H, Aragão F, Marguet S, de la Fuente B, Muñoz MJ, et al. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. PLoS One. 2021 Apr 8;16(4):e0249515.; https://hdl.handle.net/11351/5980Test

  7. 17
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Poveda A Oncogynecologic Department, Initia Oncology, Hospital Quironsalud Valencia, Avda Blasco Ibañez, 14, 46 010 Valencia, Spain. Oaknin A, Fariñas-Madrid L Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Romero I, Guerrero-Zotano A Department of Medical Oncology, Fundación Instituto Valenciano de Oncología (IVO), Valencia, Spain. Rodriguez-Freixinos V Department of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Scientific Reports;11; https://doi.org/10.1038/s41598-021-82671-wTest; Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, et al. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Sci Rep. 2021 Dec 24;11:4433.; https://hdl.handle.net/11351/5965Test; 000626806200025

  8. 18
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, García-Layana A, Recalde S, Hernandez M Retinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clínica Universidad de Navarra, 31008 Pamplona, Spain. Navarra Institute for Health Research, IdiSNA, 31008 Pamplona, Spain. Red Temática de Investigación Cooperativa Sanitaria en Enfer-Medades Oculares (Oftared), Instituto de Salud Carlos III, 28029 Madrid, Spain. Abraldes MJ Red Temática de Investigación Cooperativa Sanitaria en Enfer-Medades Oculares (Oftared), Instituto de Salud Carlos III, 28029 Madrid, Spain. Nascimento J Retinal Department, Ophthalmology, Retina Lisbon Institut, 1050-085 Lisbon, Portugal. Hernández-Galilea E Department of Ophthalmology, University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain. Zapata MA Servei d’Oftalmologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Nutrients;13(4); https://doi.org/10.3390/nu13041253Test; info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0008%2F0011; García-Layana A, Recalde S, Hernandez M, Abraldes MJ, Nascimento J, Hernández-Galilea E, et al. A Randomized Study of Nutritional Supplementation in Patients with Unilateral Wet Age-Related Macular Degeneration. Nutrients. 2021 Apr;13(4):1253.; https://hdl.handle.net/11351/6781Test; 000643404600001

  9. 19
    تقرير
  10. 20

    المساهمون: Institut Català de la Salut, [Hollebecque A] Gustave Roussy, Département d’innovation thérapeutique et essais précoces, Villejuif, France. [Salvagni S] S. Orsola Polyclinic, Malpighi University Hospital, Bologna, Italy. [Plummer R] Clinical and Translational Research Institute Northern, Newcastle University, Newcastle, UK. [Niccoli P] Department of Medical Oncology, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France. [Capdevila J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. IOB-Teknon, Barcelona, Spain. [Curigliano G] European Institute of Oncology, IRCCS, University of Milan, Milan, Italy, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf